Status: Recruiting
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting toxicities (DLTs) following single weekly or multiple-day weekly dose regimens of single-agent, oral ONC206 in patients with recurrent, primary central nervous system (CNS) neoplasms.
Participants needed: 102
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Jazz PharmaceuticalsUpdated: Dec 18, 2025Locations: 1
Eligibility criteria
Patients aged ≥18 years with a recurrent, primary CNS neoplasm. For all cohorts,... [+21]
(Exclusion Criterion #1 was removed in Amendment 3) [+33]